An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Movantik

Chemical Namenaloxegol
Dosage FormTablet (oral; 12.5mg, 25mg)
Drug ClassReceptor antagonists
SystemDigestion
CompanyAstraZeneca
Approval Year2014

Indication

  • For the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Movantik (naloxegol) Prescribing Information2014AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation.2020Alimentary Pharmacology and Therapeutics
Management of opioid-induced and non–opioid-related constipation in patients with cancer: Systematic review and meta-analysis. 2020Oncology Nursing Forum
Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis.2018Clinical Gastroenterology and Hepatology
Drugs for treating opioid-induced constipation: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials.2018Journal of Pain and Symptom Management
The efficacy of peripheral opioid antagonists in opioid-induced constipation and postoperative ileus: A systematic review of the literature.2017Regional Anesthesia and Pain Medicine